Mitsubishi Tanabe Pharma Corporation

Sanofi-aventis

Sanofi

Satoshi Yokoshima

Kazutoshi Watanabe

Kenji Fukunaga

Toshiyuki Kohara

Fumiaki Uehara

Shinsuke Hiki

Yoshihiro Usui

Masahiro Okuyama

Kazuki Nakayama

Aya Shoda

Daiki Sakai

Keiichi Aritomo

Shin-ichi Kusaka

Fumiaki Mitsubishi Pharma Corporation Uehara

Shinsuke Mitsubishi Pharma Corporation Hiki

Kazutoshi Mitsubishi Pharma Corporation Watanabe

Kenji Mitsubishi Pharma Corporation Fukunaga

Toshiyuki Mitsubishi Pharma Corporation Kohara

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein Rrepresents a hydrogen or the like; Rrepresents methyl group or the like; Rrepresents a halogen atom or the like; q represents an integer of 0 to 3; Z represent nitrogen atom, CH, or the like; Rrepresents hydrogen or the like; Rrepresents hydrogen or the like; Rrepresents a substituted alkyloxy and the like; p represents an integer of 0 to 3; X represents bond, CH, oxygen atom, NH, or the like; any one or more of Rand R, Rand R, Rand R, X and R, X and R, X and R, and Rand Rmay combine to each other to form a ring, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

2-(cyclic amino)-pyrimidone derivatives

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein Rrepresents a C-Calkyl; Rrepresents a hydrogen atom or the like; Rrepresents a halogen or the like; q represents an integer of 1 to 7; Rrepresents a halogen or the like; p represents 0 or an integer of 1 to 5; Rrepresents a C-Caryl, a heterocycle or the like; and X represents oxygen, NH, or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).

6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors

A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C-Calkyl; Rrepresents a hydrogen atom, or the like; R' represents a C-Calkyl or the like; q represents 0 or an integer of 1 to 7; Y represents a C-Calkyl or the like; p represents 0 or an integer of 1 to 5; R represents a 2,3-dihydroindolyl or the like, which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease). 

2-morpholino-4-pyrimidone compound

A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C-Calkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C-Calkyl group, an optionally partially hydrogenated C-Caryl ring, an indan ring or the like; m represents an integer of 1 to 3; each independently represents a halogen atom, a hydroxy group, a cyano group, a C-Calkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C-Calkylene group. 

2,3,6-Trisubstituted-4-pyrimidone derivatives

Growing community of inventors

Tokyo, Japan

Satoshi Yokoshima